THE APEX TIMES
The White House withdrew Heidi Overton’s nomination to lead the Food and Drug Administration, multiple outlets reported, citing opposition from Senate Republicans and timing tied to a health committee vote.
The White House has withdrawn Heidi Overton’s nomination to lead the Food and Drug Administration, according to reporting by The Hill and other national outlets late Tuesday. The withdrawal came on the eve of a planned Senate committee vote, where Overton was expected to face scrutiny in a health panel controlled by Republicans by a single-seat margin.
The Hill, citing its sister network NewsNation, reported that the move followed opposition from Senate Republicans. In the same reporting, the vote was scheduled for Wednesday in the Senate health committee, where Republicans hold only a one-vote majority, a narrow margin that can make confirmation efforts vulnerable to internal dissent.
CBS News and Fox News also reported the withdrawal, describing it as happening shortly before the Senate panel consideration. The Guardian likewise reported that the nomination was pulled, linking the timing to the committee process.
The nomination withdraws Overton from the formal confirmation track at the committee stage, at least for the current timeline described in the reporting. A withdrawal can leave the FDA leadership question unresolved until the administration submits a new nominee or chooses another course for interim leadership, subject to statutory and agency continuity requirements.
The reported opposition adds to an ongoing pattern in which FDA commissioners and other senior health officials face intense review over regulatory approaches and oversight priorities. In the Senate, committee votes are often treated as a gatekeeping step, and a one-seat majority can elevate the effect of individual members’ concerns.
With the withdrawal reported but not confirmed through an identified White House release, Federal Register notice, or Senate record in the materials provided, the practical next step depends on whether the administration names a successor or changes strategy for reintroducing a nomination in the Senate.
If the administration sends a new nomination, it would generally restart the Senate’s process, including committee consideration and the possibility of additional floor action, meaning the timetable for filling the FDA top leadership role would likely move further into the next legislative calendar.
Comments
Community guidelines. Comments may be removed for violations.
Loading comments...